p16(CDKN2) gene polymorphism:: association with histologic subtypes of epithelial ovarian cancer in China

被引:18
|
作者
Yan, L. [1 ,2 ]
Na, W. [2 ]
Shan, K. [3 ]
Xiao-Wei, M. [3 ]
Wei, G. [2 ]
Shu-Cheng, C. [3 ]
机构
[1] Hebei Med Univ, Hosp 4, Hebei Canc Inst, Shijiazhuang 050011, Peoples R China
[2] Hebei Med Univ, Hosp 4, Dept Mol Biol, Shijiazhuang 050011, Peoples R China
[3] Hebei Med Univ, Hosp 4, Dept Obstet & Gynaecol, Shijiazhuang 050011, Peoples R China
基金
美国国家科学基金会;
关键词
epithelial ovarian cancer; haplotype; p16; single nucleotide polymorphism; susceptibility;
D O I
10.1111/j.1525-1438.2007.00953.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
p16 is an important tumor suppressor gene, which is inactivated in many kinds of tumors. The common variants of p16 may be associated with the risk of certain tumors development. We analyzed the frequency of two adjacent polymorphisms in p16 exon 3 (540C -> G and 580C -> T) and their haplotype in blood samples from epithelial ovarian cancer (EOC) patients and healthy controls using polymerase chain reaction-restriction fragment length polymorphism. The results showed that the genotype frequency of p16 580C -> T polymorphism was significantly different among histologic subtypes of EOC (P = 0.02). T allele carriers significantly reduced the risk of serous EOC; the adjusted odds ratio was 0.40 (95% CI = 0.19-0.84). There are neither association between p16 540C -> G polymorphism and EOC development, progression, nor association between the haplotypes of two single nucleotide polymorphisms and the tumor development. Our results suggested that the p16 580C -> T polymorphism might affect the individual susceptibility to specific subtypes of EOC. Different types of ovarian cancer might adopt distinct carcinogenetic pathways. However, this result may be further validated in a larger sample of patients.
引用
收藏
页码:30 / 35
页数:6
相关论文
共 50 条
  • [41] p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression
    Piccinin, S
    Doglioni, C
    Maestro, R
    Vukosavljevic, T
    Gasparotto, D
    DOrazi, C
    Boiocchi, M
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1997, 74 (01) : 26 - 30
  • [42] Expression of p16 tumor suppressor gene in epithelial ovarian cancer
    Li, A
    Dionyssios, K
    Abreo, F
    Fracchioli, S
    Turbat-Herrera, EA
    Singal, R
    Li, B
    Yu, H
    [J]. MODERN PATHOLOGY, 2002, 15 (01) : 201A - 202A
  • [43] The tribulations of the tumor suppressor gene p16/MTS1/CDKN2: A continuing saga
    Larsen, CJ
    [J]. BULLETIN DU CANCER, 1997, 84 (04) : 427 - 430
  • [44] Transfer of p16(inka)/CDKN2 gene in leukaemic cell lines inhibits cell proliferation
    Quesnel, B
    Preudhomme, C
    Lepelley, P
    Hetuin, D
    Vanrumbeke, M
    Bauters, F
    Velu, T
    Fenaux, P
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (02) : 291 - 298
  • [45] FREQUENCY OF HOMOZYGOUS DELETION AT P16/CDKN2 IN PRIMARY HUMAN TUMORS
    CAIRNS, P
    POLASCIK, TJ
    EBY, Y
    TOKINO, K
    CALIFANO, J
    MERLO, A
    MAO, L
    HERATH, J
    JENKINS, R
    WESTRA, W
    RUTTER, JL
    BUCKLER, A
    GABRIELSON, E
    TOCKMAN, M
    CHO, KR
    HEDRICK, L
    BOVA, GS
    ISAACS, W
    KOCH, W
    SCHWAB, D
    SIDRANSKY, D
    [J]. NATURE GENETICS, 1995, 11 (02) : 210 - 212
  • [46] Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma
    ElNaggar, AK
    Lai, SL
    Clayman, G
    Lee, JKJ
    Luna, MA
    Goepfert, H
    Batsakis, JG
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1997, 151 (06): : 1767 - 1774
  • [47] MUTATION FREQUENCY OF THE P16/CDKN2 GENE IN PRIMARY CANCERS IN THE UPPER DIGESTIVE-TRACT
    IGAKI, H
    SASAKI, H
    TACHIMORI, Y
    KATO, H
    WATANABE, H
    KIMURA, T
    HARADA, Y
    SUGIMURA, T
    TERADA, M
    [J]. CANCER RESEARCH, 1995, 55 (15) : 3421 - 3423
  • [48] Expression of p16 tumor suppressor gene in epithelial ovarian cancer
    Li, A
    Dionyssios, K
    Abreo, F
    Fracchioli, S
    Turbat-Herrera, EA
    Singal, R
    Li, B
    Yu, H
    [J]. LABORATORY INVESTIGATION, 2002, 82 (01) : 201A - 202A
  • [49] Molecular analysis of CDKN2 (p16) in gliomas associated with clinical data
    Nascimento, PD
    Maciel, CM
    Kawamura, MT
    Oliveira, JA
    Teixeira, A
    Carvalho, MDC
    Alves, G
    [J]. ONCOLOGY REPORTS, 2001, 8 (05) : 1039 - 1043
  • [50] p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma
    Busatto, G
    Shiao, YH
    Parenti, AR
    Baffa, R
    Ruol, A
    Plebani, M
    Rugge, M
    [J]. JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1998, 51 (02): : 80 - 84